Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects

Lam T. Khuat, Logan V. Vick, Cordelia Dunai, Craig P. Collins, Shyam K. More, Catherine T. Le, Chien Chun Steven Pai, Kevin M. Stoffel, Emanual Maverakis, Robert J. Canter, Arta M. Monjazeb, Dan L. Longo, Mehrdad Abedi, Eunju Choi, Bruce R. Blazar, Maneesh Dave, William J. Murphy

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a potential curative option for treating a variety of hematologic diseases, but acute and chronic graft-versus-host disease (GVHD) remain major barriers limiting efficacy. Acute gut GVHD occurs with marked increases in proinflammatory cytokines (including TNF and IL-6), which we recently demonstrated was exacerbated in obesity resulting in severe gastrointestinal pathology. Given the pleiotropic and overlapping effects of these 2 cytokines, we assessed the impact of dual TNF and IL-6R blockade on GVHD as well as graft-versus tumor (GVT) effects in different mouse GVHD models. Early administration of combined blockade resulted in greater protection and survival from acute gut GVHD compared with single blockade regimens and even development of later chronic skin GVHD. Importantly, double cytokine blockade preserved GVT effects reinforcing that GVT and GVHD can be delineated and may result in greater efficacy in allo-HSCT.

Original languageEnglish (US)
Pages (from-to)2583-2588
Number of pages6
JournalBlood
Volume138
Issue number24
DOIs
StatePublished - Dec 16 2021

Bibliographical note

Funding Information:
This work was funded by National Institutes of Health (NIH), National Cancer Institute R01 CA214048 (W.J.M.), NIH, National Institute of Allergy and Infectious Diseases R37 AI34495, NIH, National Heart, Lung, and Blood Institute HL56067 (B.R.B.) and the UC Davis Comprehensive Cancer Center Support Grant (CCSG) (P30 CA093373). M.D. is supported by NIH, National Institute of Diabetes and Digestive and Kidney Diseases K08DK110421.

Funding Information:
The authors thank Sean Judge and Hyeongsun Moon for their expertise and insightful feedback and suggestions. They also thank Weihong Ma from the W.J.M. laboratory, and Qian Chen in the UC Davis Pathology Core for their technical expertise and help. This work was funded by National Institutes of Health (NIH), National Cancer Institute R01 CA214048 (W.J.M.), NIH, National Institute of Allergy and Infectious Diseases R37 AI34495, NIH, National Heart, Lung, and Blood Institute HL56067 (B.R.B.) and the UC Davis Comprehensive Cancer Center Support Grant (CCSG) (P30 CA093373). M.D. is supported by NIH, National Institute of Diabetes and Digestive and Kidney Diseases K08DK110421. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.

Publisher Copyright:
© 2021 American Society of Hematology

Fingerprint

Dive into the research topics of 'Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects'. Together they form a unique fingerprint.

Cite this